Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome.

Hooper JW, Brocato RL, Kwilas SA, Hammerbeck CD, Josleyn MD, Royals M, Ballantyne J, Wu H, Jiao JA, Matsushita H, Sullivan EJ.

Sci Transl Med. 2014 Nov 26;6(264):264ra162. doi: 10.1126/scitranslmed.3010082.

2.

DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS).

Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW.

PLoS One. 2012;7(4):e35996. doi: 10.1371/journal.pone.0035996. Epub 2012 Apr 27.

3.

A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Hooper JW, Josleyn M, Ballantyne J, Brocato R.

Vaccine. 2013 Sep 13;31(40):4314-21. doi: 10.1016/j.vaccine.2013.07.025. Epub 2013 Jul 24.

4.
5.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, Hammerbeck CD, Schiltz J, Royals M, Ballantyne J, Hooper JW, Bradley DS.

PLoS Negl Trop Dis. 2015 Jun 5;9(6):e0003803. doi: 10.1371/journal.pntd.0003803. eCollection 2015.

6.

Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.

Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW.

J Virol. 2003 Sep;77(18):9894-905.

7.

A lethal disease model for hantavirus pulmonary syndrome in immunosuppressed Syrian hamsters infected with Sin Nombre virus.

Brocato RL, Hammerbeck CD, Bell TM, Wells JB, Queen LA, Hooper JW.

J Virol. 2014 Jan;88(2):811-9. doi: 10.1128/JVI.02906-13. Epub 2013 Nov 6.

8.
9.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

10.

Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.

Hooper JW, Ferro AM, Wahl-Jensen V.

J Virol. 2008 Feb;82(3):1332-8. Epub 2007 Nov 21.

11.

Glycoprotein-Specific Antibodies Produced by DNA Vaccination Protect Guinea Pigs from Lethal Argentine and Venezuelan Hemorrhagic Fever.

Golden JW, Maes P, Kwilas SA, Ballantyne J, Hooper JW.

J Virol. 2016 Jan 20;90(7):3515-29. doi: 10.1128/JVI.02969-15.

13.

Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H.

J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.

14.

Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters.

McElroy AK, Smith JM, Hooper JW, Schmaljohn CS.

Virology. 2004 Aug 15;326(1):130-9.

15.

Hantaan/Andes virus DNA vaccine elicits a broadly cross-reactive neutralizing antibody response in nonhuman primates.

Hooper JW, Custer DM, Smith J, Wahl-Jensen V.

Virology. 2006 Mar 30;347(1):208-16. Epub 2005 Dec 27.

16.

Ribavirin protects Syrian hamsters against lethal hantavirus pulmonary syndrome--after intranasal exposure to Andes virus.

Ogg M, Jonsson CB, Camp JV, Hooper JW.

Viruses. 2013 Nov 8;5(11):2704-20. doi: 10.3390/v5112704.

17.

Neutralizing antibodies in survivors of Sin Nombre and Andes hantavirus infection.

Valdivieso F, Vial P, Ferres M, Ye C, Goade D, Cuiza A, Hjelle B.

Emerg Infect Dis. 2006 Jan;12(1):166-8.

18.

Sin nombre virus (SNV) Ig isotype antibody response during acute and convalescent phases of hantavirus pulmonary syndrome.

Bostik P, Winter J, Ksiazek TG, Rollin PE, Villinger F, Zaki SR, Peters CJ, Ansari AA.

Emerg Infect Dis. 2000 Mar-Apr;6(2):184-7.

19.

Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome.

Safronetz D, Falzarano D, Scott DP, Furuta Y, Feldmann H, Gowen BB.

Antimicrob Agents Chemother. 2013 Oct;57(10):4673-80. doi: 10.1128/AAC.00886-13. Epub 2013 Jul 15.

20.

Supplemental Content

Support Center